Rx Africa Ethiopia to introduce 36 new drugs in 2009
According to the company, the malaria drug Artemisinin is scheduled for a third-quarter launch in 2009, and HIV/AIDS pharmaceuticals are in process. Mulugetta Bezzabeh, CEO of Rx for
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The companies intend to provide a highly integrated platform for structure-based drug discovery with one stop shop for structure-guided discovery, chemistry, biology and structural biology capabilities. This arrangement
At Abraxis Health, Dr Ploeg will be responsible for building and integrating the company’s evidenced-based medicine capabilities, drug-discovery efforts and external partnerships that will serve as the foundation